CN113693955A - 一种精华液 - Google Patents
一种精华液 Download PDFInfo
- Publication number
- CN113693955A CN113693955A CN202011069709.9A CN202011069709A CN113693955A CN 113693955 A CN113693955 A CN 113693955A CN 202011069709 A CN202011069709 A CN 202011069709A CN 113693955 A CN113693955 A CN 113693955A
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- essence
- sodium hyaluronate
- hydroxyacetophenone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 51
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 44
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 23
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 23
- 239000004475 Arginine Substances 0.000 claims abstract description 21
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims abstract description 21
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 21
- 108010087806 Carnosine Proteins 0.000 claims abstract description 21
- 239000004472 Lysine Substances 0.000 claims abstract description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 21
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940044199 carnosine Drugs 0.000 claims abstract description 21
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 21
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 20
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 19
- 108010024636 Glutathione Proteins 0.000 claims abstract description 19
- 229940080421 coco glucoside Drugs 0.000 claims abstract description 19
- 229960003180 glutathione Drugs 0.000 claims abstract description 19
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 19
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 17
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 17
- -1 tetrapeptide-1 Substances 0.000 claims abstract description 13
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 5
- 229960003121 arginine Drugs 0.000 claims abstract description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 13
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 13
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 6
- 241000208327 Apocynaceae Species 0.000 claims description 5
- 235000003069 Artemisia scoparia Nutrition 0.000 claims description 5
- 241001249148 Artemisia scoparia Species 0.000 claims description 5
- 241000208838 Asteraceae Species 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 73
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 26
- 230000032683 aging Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 7
- 231100000245 skin permeability Toxicity 0.000 abstract description 6
- 239000013589 supplement Substances 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 108010035532 Collagen Proteins 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 210000004207 dermis Anatomy 0.000 abstract description 3
- 210000001339 epidermal cell Anatomy 0.000 abstract description 3
- 210000002950 fibroblast Anatomy 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 27
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 230000037393 skin firmness Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 235000008658 Artemisia capillaris Nutrition 0.000 description 2
- 241000092668 Artemisia capillaris Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 241000331436 Tylophora floribunda Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241001038563 Pseudostellaria Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种精华液,该精华液组分包括水、九肽‑1、四肽‑1、甘油、丁二醇、烟酰胺、肌肽、椰油基葡糖苷、精氨酸/赖氨酸多肽、棕榈酰三肽‑8、对羟基苯乙酮、1,2己二醇、透明质酸钠、谷胱甘肽和EDTA二钠,本发明的有益效果是:能够增加肌肤通透性,补充水分,防护肌肤变暗,提亮肌肤光泽,使皮肤细嫩光滑,九肽‑1、四肽‑1、肌肽、精氨酸/赖氨酸多肽、棕榈酰三肽‑8使精华液具有非常强的皮肤渗透力,可快速激活表皮细胞,为肌肤补充营养,激发真皮层的成纤维母细胞,加快合成胶原蛋白,保护皮肤充足水分,精华液具有调节新陈代谢,让皮肤更健康,抑制黑色素,清除自由基,延缓衰老,消炎舒缓,补水亮白,抗敏修复。
Description
技术领域
本发明公开了一种精华液,属于护肤技术领域。
背景技术
随着年龄的增长,皮肤老化,其保湿作用及屏障功能逐渐减弱,天然保湿因子含量减少;肌肤的生理性老化以及眼部肌肉的长期收期收缩,长期干燥缺水会大大加速它的产生,再加上眼部周围肌肤缺乏皮脂腺,干燥便成了最容易遭遇的问题,这也是为什么细纹最先光顾眼睛的缘由。环境因素造成的细纹,色斑,是指和周围颜色不同的斑点。包括雀斑、黑斑、黄褐斑和老年斑等,属色素障碍性皮肤病。由于皮肤黑色素的增加而形成的一种常见面部呈褐色或黑色素沉着性、损容性的皮肤疾病,多发于面颊和前额部位,日晒后加重,多见于女性,与妊娠、长期月经紊乱有关,精华素是用于脸部的护肤品中的一种,含有较珍贵的功效成分,如植物提取物、神经酰胺、角鲨烷等,它的作用有防衰老、抗皱、保湿、美白、去斑等等。精华素通常使用在护肤水之后,乳液或面霜之前。由于精华液中富含多种功效成分且浓度较高,通常价格较其他化妆品更加昂贵。
目前精华素的渗透效果较差,有效成分难以快速渗透皮肤,护肤效果不理想,对皮肤容易造成刺激,尤其是敏感肌人群,使用受限,实用性较差。
发明内容
本发明要解决的技术问题是克服目前精华素的渗透效果较差,有效成分难以快速渗透皮肤,护肤效果不理想,对皮肤容易造成刺激,尤其是敏感肌人群,使用受限的问题,提供一种精华液。
为实现上述目的,本发明提供如下技术方案:一种精华液,该精华液组分包括水、九肽-1、四肽-1、甘油、丁二醇、烟酰胺、肌肽、椰油基葡糖苷、精氨酸/赖氨酸多肽、棕榈酰三肽-8、对羟基苯乙酮、1,2己二醇、透明质酸钠、谷胱甘肽和EDTA二钠;
作为本发明的一种优选技术方案,所述精华液组分的质量百分比为:70-80%份水、5-7%份九肽-1、3-5%份四肽-1、2-6%份甘油、2.1-3.6%份丁二醇、1.5-3.5%份烟酰胺、1-3%份肌肽、0.2-0.5%份椰油基葡糖苷、0.1-0.5%份精氨酸/赖氨酸多肽、0.2-0.4%份棕榈酰三肽-8、0.4-0.6%份对羟基苯乙酮、0.45-0.6%份1,2己二醇、0.07-0.15%份透明质酸钠、0.1-0.4%份谷胱甘肽和0.01-0.06%份EDTA二钠。
作为本发明的一种优选技术方案,所述精华液组分的质量百分比为:78份水、5%份九肽-1、3%份四肽-1、6%份甘油、3.1%份丁二醇、2%份烟酰胺、1%份肌肽、0.3%份椰油基葡糖苷、0.2%份精氨酸/赖氨酸多肽、0.2%份棕榈酰三肽-8、0.4%份对羟基苯乙酮、0.45%份1,2己二醇、0.12%份透明质酸钠、0.2%份谷胱甘肽和0.03%份EDTA二钠。
作为本发明的一种优选技术方案,所述精华液组分的质量百分比为:76%份水、6%份九肽-1、4%份四肽-1、4%份甘油、3%份丁二醇、2.5%份烟酰胺、2%份肌肽、0.4%份椰油基葡糖苷、0.3%份精氨酸/赖氨酸多肽、0.3%份棕榈酰三肽-8、0.5%份对羟基苯乙酮、0.56%份1,2己二醇、0.1%份透明质酸钠、0.3%份谷胱甘肽和0.04%份EDTA二钠。
作为本发明的一种优选技术方案,所述精华液组分的质量百分比为:74%份水、7%份九肽-1、5%份四肽-1、2%份甘油、2.9%份丁二醇、3%份烟酰胺、3%份肌肽、0.5%份椰油基葡糖苷、0.5%份精氨酸/赖氨酸多肽、0.4%份棕榈酰三肽-8、0.6%份对羟基苯乙酮、0.5%份1,2己二醇、0.15%份透明质酸钠、0.4%份谷胱甘肽和0.05%份EDTA二钠。
作为本发明的一种优选技术方案,所述透明质酸钠采用小分子透明质酸钠。
作为本发明的一种优选技术方案,所述水采用去离子水。
作为本发明的一种优选技术方案,所述对羟基苯乙酮采用天然植物提取物,由菊科植物滨蒿的茎、叶,茵陈蒿、萝藦科植物、人参娃儿藤植物的根中提取。
与现有技术相比,本发明的有益效果:本精华液与传统的精华液相比较,能够增加肌肤通透性,补充水分,防护肌肤变暗,提亮肌肤光泽,使皮肤细嫩光滑;
九肽-1:作为促黑色素细胞激素的对抗剂,阻止酪氨酸酶进一步被激活而产生黑色素,能从源头抑制黑色素形成,减少色素沉着,控制皮肤色调和防止褐斑产生,无细胞毒性,安全无刺激;
四肽-1:具有抗氧性,可抑制皮肤老化,改善皮肤的弹性和紧实度,滋润和光滑皮肤的效果,四肽-1与皮肤的相容性佳,易吸收,具有良好的防老抗老、皮肤养护、美白效果;
烟酰胺:能够加速皮肤细胞的代谢,促进角质层的循环,让肌肤更年轻、更有活力,同时它具有一定的抗氧化作用,能使皮肤保持弹性;减少黑色素向细胞的运输,可以美白祛斑,加速黑色素的代谢和剥落,烟酰胺可以阻止黑色素向角质形成细胞的转运;以及能够修复角质层,强化皮肤自身的防御能力,同时具有一定的锁水的功效;
肌肽:能起到增白皮肤、防止肌肤衰老的作用;
椰油基葡糖苷:绿色表面活性剂,与其他表面活性剂复配使用能达到增稠和降低刺激的效果;
精氨酸/赖氨酸多肽:与皮肤的相容性佳,不易过敏,具有较好的防老、抗皱效果,对皮肤、眼睛的刺激性很低;
棕榈酰三肽-8:对皮肤具有保湿作用,形成一个保护网锁水网,能促进胶原蛋白的生出,具有抗炎、抗刺激及舒缓作用,可以预防和缓解由化学刺激引发的炎症和症状;具有重建和修复皮肤的功效,可以改善皮肤紧致和弹性,适用于促进皮肤紧致;
对羟基苯乙酮:是一种天然植物提取物,天然存在于菊科植物滨蒿的茎、叶,茵陈蒿、萝藦科植物、人参娃儿藤等植物的根中,具有防腐、抗氧化和舒缓作用的多功能化妆品成分,并且在高低PH和温度范围内都有优异的稳定性;
1,2己二醇:是一种小分子保湿剂,有锁水和抗菌功能;
谷胱甘肽:具有抗氧化作用,能够淡化色斑与年龄斑,代谢毒素、抵御自由基,减少细纹与皱纹,增强肌肤弹性并延缓衰老;
EDTA二钠:是一种络合缓释剂,能调节化妆品的酸碱度,能自动调节化妆品的酸碱性在皮肤能适合的范围内,以保护皮肤不受强的刺激;
九肽-1、四肽-1、肌肽、精氨酸/赖氨酸多肽、棕榈酰三肽-8使精华液具有非常强的皮肤渗透力,可快速激活表皮细胞,为肌肤补充营养,激发真皮层的成纤维母细胞,加快合成胶原蛋白,保护皮肤充足水分,精华液具有调节新陈代谢,让皮肤更健康,抑制黑色素,清除自由基,延缓衰老,消炎舒缓,补水亮白,抗敏修复。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
一种精华液,该精华液组分包括水、九肽-1、四肽-1、甘油、丁二醇、烟酰胺、肌肽、椰油基葡糖苷、精氨酸/赖氨酸多肽、棕榈酰三肽-8、对羟基苯乙酮、1,2己二醇、透明质酸钠、谷胱甘肽和EDTA二钠;
进一步的,所述精华液组分的质量百分比为:70-80%份水、5-7%份九肽-1、3-5%份四肽-1、2-6%份甘油、2.1-3.6%份丁二醇、1.5-3.5%份烟酰胺、1-3%份肌肽、0.2-0.5%份椰油基葡糖苷、0.1-0.5%份精氨酸/赖氨酸多肽、0.2-0.4%份棕榈酰三肽-8、0.4-0.6%份对羟基苯乙酮、0.45-0.6%份1,2己二醇、0.07-0.15%份透明质酸钠、0.1-0.4%份谷胱甘肽和0.01-0.06%份EDTA二钠。
进一步的,所述精华液组分的质量百分比为:78份水、5%份九肽-1、3%份四肽-1、6%份甘油、3.1%份丁二醇、2%份烟酰胺、1%份肌肽、0.3%份椰油基葡糖苷、0.2%份精氨酸/赖氨酸多肽、0.2%份棕榈酰三肽-8、0.4%份对羟基苯乙酮、0.45%份1,2己二醇、0.12%份透明质酸钠、0.2%份谷胱甘肽和0.03%份EDTA二钠。
进一步的,所述精华液组分的质量百分比为:76%份水、6%份九肽-1、4%份四肽-1、4%份甘油、3%份丁二醇、2.5%份烟酰胺、2%份肌肽、0.4%份椰油基葡糖苷、0.3%份精氨酸/赖氨酸多肽、0.3%份棕榈酰三肽-8、0.5%份对羟基苯乙酮、0.56%份1,2己二醇、0.1%份透明质酸钠、0.3%份谷胱甘肽和0.04%份EDTA二钠。
进一步的,所述精华液组分的质量百分比为:74%份水、7%份九肽-1、5%份四肽-1、2%份甘油、2.9%份丁二醇、3%份烟酰胺、3%份肌肽、0.5%份椰油基葡糖苷、0.5%份精氨酸/赖氨酸多肽、0.4%份棕榈酰三肽-8、0.6%份对羟基苯乙酮、0.5%份1,2己二醇、0.15%份透明质酸钠、0.4%份谷胱甘肽和0.05%份EDTA二钠。
其中,所述透明质酸钠采用小分子透明质酸钠。
其中,所述水采用去离子水。
其中,所述对羟基苯乙酮采用天然植物提取物,由菊科植物滨蒿的茎、叶,茵陈蒿、萝藦科植物、人参娃儿藤植物的根中提取。
具体的,该精华液组分包括水、九肽-1、四肽-1、甘油、丁二醇、烟酰胺、肌肽、椰油基葡糖苷、精氨酸/赖氨酸多肽、棕榈酰三肽-8、对羟基苯乙酮、1,2己二醇、透明质酸钠、谷胱甘肽和EDTA二钠,本精华液与传统的精华液相比较,能够增加肌肤通透性,补充水分,防护肌肤变暗,提亮肌肤光泽,使皮肤细嫩光滑;九肽-1:作为促黑色素细胞激素的对抗剂,阻止酪氨酸酶进一步被激活而产生黑色素,能从源头抑制黑色素形成,减少色素沉着,控制皮肤色调和防止褐斑产生,无细胞毒性,安全无刺激;四肽-1:具有抗氧性,可抑制皮肤老化,改善皮肤的弹性和紧实度,滋润和光滑皮肤的效果,四肽-1与皮肤的相容性佳,易吸收,具有良好的防老抗老、皮肤养护、美白效果;烟酰胺:能够加速皮肤细胞的代谢,促进角质层的循环,让肌肤更年轻、更有活力,同时它具有一定的抗氧化作用,能使皮肤保持弹性;减少黑色素向细胞的运输,可以美白祛斑,加速黑色素的代谢和剥落,烟酰胺可以阻止黑色素向角质形成细胞的转运;以及能够修复角质层,强化皮肤自身的防御能力,同时具有一定的锁水的功效;肌肽:能起到增白皮肤、防止肌肤衰老的作用;椰油基葡糖苷:绿色表面活性剂,与其他表面活性剂复配使用能达到增稠和降低刺激的效果;精氨酸/赖氨酸多肽:与皮肤的相容性佳,不易过敏,具有较好的防老、抗皱效果,对皮肤、眼睛的刺激性很低;棕榈酰三肽-8:对皮肤具有保湿作用,形成一个保护网锁水网,能促进胶原蛋白的生出,具有抗炎、抗刺激及舒缓作用,可以预防和缓解由化学刺激引发的炎症和症状;具有重建和修复皮肤的功效,可以改善皮肤紧致和弹性,适用于促进皮肤紧致;对羟基苯乙酮:是一种天然植物提取物,天然存在于菊科植物滨蒿的茎、叶,茵陈蒿、萝藦科植物、人参娃儿藤等植物的根中,具有防腐、抗氧化和舒缓作用的多功能化妆品成分,并且在高低PH和温度范围内都有优异的稳定性;1,2己二醇:是一种小分子保湿剂,有锁水和抗菌功能;谷胱甘肽:具有抗氧化作用,能够淡化色斑与年龄斑,代谢毒素、抵御自由基,减少细纹与皱纹,增强肌肤弹性并延缓衰老;EDTA二钠:是一种络合缓释剂,能调节化妆品的酸碱度,能自动调节化妆品的酸碱性在皮肤能适合的范围内,以保护皮肤不受强的刺激;
综上,精华液组分中的九肽-1、四肽-1、肌肽、精氨酸/赖氨酸多肽、棕榈酰三肽-8使精华液具有非常强的皮肤渗透力,可快速激活表皮细胞,为肌肤补充营养,激发真皮层的成纤维母细胞,加快合成胶原蛋白,保护皮肤充足水分,精华液具有调节新陈代谢,让皮肤更健康,抑制黑色素,清除自由基,延缓衰老,消炎舒缓,补水亮白,抗敏修复。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (8)
1.一种精华液,其特征在于,该精华液组分包括水、九肽-1、四肽-1、甘油、丁二醇、烟酰胺、肌肽、椰油基葡糖苷、精氨酸/赖氨酸多肽、棕榈酰三肽-8、对羟基苯乙酮、1,2己二醇、透明质酸钠、谷胱甘肽和EDTA二钠。
2.根据权利要求1所述的一种精华液,其特征在于:所述精华液组分的质量百分比为:70-80%份水、5-7%份九肽-1、3-5%份四肽-1、2-6%份甘油、2.1-3.6%份丁二醇、1.5-3.5%份烟酰胺、1-3%份肌肽、0.2-0.5%份椰油基葡糖苷、0.1-0.5%份精氨酸/赖氨酸多肽、0.2-0.4%份棕榈酰三肽-8、0.4-0.6%份对羟基苯乙酮、0.45-0.6%份1,2己二醇、0.07-0.15%份透明质酸钠、0.1-0.4%份谷胱甘肽和0.01-0.06%份EDTA二钠。
3.根据权利要求2所述的一种精华液,其特征在于:所述精华液组分的质量百分比为:78份水、5%份九肽-1、3%份四肽-1、6%份甘油、3.1%份丁二醇、2%份烟酰胺、1%份肌肽、0.3%份椰油基葡糖苷、0.2%份精氨酸/赖氨酸多肽、0.2%份棕榈酰三肽-8、0.4%份对羟基苯乙酮、0.45%份1,2己二醇、0.12%份透明质酸钠、0.2%份谷胱甘肽和0.03%份EDTA二钠。
4.根据权利要求2所述的一种精华液,其特征在于:所述精华液组分的质量百分比为:76%份水、6%份九肽-1、4%份四肽-1、4%份甘油、3%份丁二醇、2.5%份烟酰胺、2%份肌肽、0.4%份椰油基葡糖苷、0.3%份精氨酸/赖氨酸多肽、0.3%份棕榈酰三肽-8、0.5%份对羟基苯乙酮、0.56%份1,2己二醇、0.1%份透明质酸钠、0.3%份谷胱甘肽和0.04%份EDTA二钠。
5.根据权利要求2所述的一种精华液,其特征在于:所述精华液组分的质量百分比为:74%份水、7%份九肽-1、5%份四肽-1、2%份甘油、2.9%份丁二醇、3%份烟酰胺、3%份肌肽、0.5%份椰油基葡糖苷、0.5%份精氨酸/赖氨酸多肽、0.4%份棕榈酰三肽-8、0.6%份对羟基苯乙酮、0.5%份1,2己二醇、0.15%份透明质酸钠、0.4%份谷胱甘肽和0.05%份EDTA二钠。
6.根据权利要求2所述的一种精华液,其特征在于:所述透明质酸钠采用小分子透明质酸钠。
7.根据权利要求2所述的一种精华液,其特征在于:所述水采用去离子水。
8.根据权利要求2所述的一种精华液,其特征在于:所述对羟基苯乙酮采用天然植物提取物,由菊科植物滨蒿的茎、叶,茵陈蒿、萝藦科植物、人参娃儿藤植物的根中提取。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011069709.9A CN113693955A (zh) | 2020-10-09 | 2020-10-09 | 一种精华液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011069709.9A CN113693955A (zh) | 2020-10-09 | 2020-10-09 | 一种精华液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113693955A true CN113693955A (zh) | 2021-11-26 |
Family
ID=78646706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011069709.9A Pending CN113693955A (zh) | 2020-10-09 | 2020-10-09 | 一种精华液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113693955A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114146032A (zh) * | 2021-12-02 | 2022-03-08 | 科丝美诗(中国)化妆品有限公司 | 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 |
CN114588062A (zh) * | 2022-03-14 | 2022-06-07 | 富丽诗(厦门)健康科技有限公司 | 一种配合5d精雕筋膜疗法使用的面部护理用精华液 |
CN114917143A (zh) * | 2022-05-19 | 2022-08-19 | 大连大学 | 一种抗皮肤衰老的海参多肽修复精华液及其制备方法 |
CN114948834A (zh) * | 2022-07-15 | 2022-08-30 | 广州市丽泽化妆品有限公司 | 一种舒缓保湿精华液及其制备方法 |
CN115778879A (zh) * | 2022-12-23 | 2023-03-14 | 蔚然(广东)生物技术有限公司 | 一种可持续舒缓修护脆弱皮肤的组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184662A (zh) * | 2019-10-18 | 2020-05-22 | 广州珂菲施诺生物科技有限公司 | 一种小分子肽肌底修护精华液 |
-
2020
- 2020-10-09 CN CN202011069709.9A patent/CN113693955A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111184662A (zh) * | 2019-10-18 | 2020-05-22 | 广州珂菲施诺生物科技有限公司 | 一种小分子肽肌底修护精华液 |
Non-Patent Citations (1)
Title |
---|
广州俏姿颜化妆品有限公司: "安肌源皙纯养肤肽精华液 备案编号粤 G妆网备字2020183497", 《网址:HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20200904120958UVF1E&NID=20200904120958UVF1E》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114146032A (zh) * | 2021-12-02 | 2022-03-08 | 科丝美诗(中国)化妆品有限公司 | 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 |
CN114588062A (zh) * | 2022-03-14 | 2022-06-07 | 富丽诗(厦门)健康科技有限公司 | 一种配合5d精雕筋膜疗法使用的面部护理用精华液 |
CN114917143A (zh) * | 2022-05-19 | 2022-08-19 | 大连大学 | 一种抗皮肤衰老的海参多肽修复精华液及其制备方法 |
CN114948834A (zh) * | 2022-07-15 | 2022-08-30 | 广州市丽泽化妆品有限公司 | 一种舒缓保湿精华液及其制备方法 |
CN115778879A (zh) * | 2022-12-23 | 2023-03-14 | 蔚然(广东)生物技术有限公司 | 一种可持续舒缓修护脆弱皮肤的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113693955A (zh) | 一种精华液 | |
KR101509608B1 (ko) | 두피 및 모발 상태 개선용 조성물 | |
US20040191330A1 (en) | Daily skin care regimen | |
EP1755547B1 (en) | Haircare compositions and methods | |
CN110384645B (zh) | 一种抗皱皮肤调理剂、美颈霜及制备方法 | |
CN111803426A (zh) | 防脱固发营养液及制备方法 | |
CN110623882A (zh) | 一种美白祛斑面膜及其制备方法 | |
KR101809266B1 (ko) | 프로폴리스 복합 추출물을 함유하는 화장료 조성물 | |
CN111184668A (zh) | 一种具有快速美白效果的美白精华液 | |
CN110755332A (zh) | 一种补水美白祛斑精华液及其制备方法 | |
CN108245454B (zh) | 一种含有天然抗氧化成分的温和洁面膏及其制备方法 | |
CN115105453A (zh) | 一种具有抗菌、消炎和修复功能的护肤品及其制备方法 | |
CN114886811A (zh) | 一种修复敏感肌肤的组合物 | |
US20140271509A1 (en) | Compositions for Skin Lightening and/or Brightening | |
KR20190023200A (ko) | 저자극성 피부 미백용 화장료 조성물 | |
CN111973501A (zh) | 一种神经酰胺赋活乳及其制备方法 | |
CN111166707B (zh) | 一种面部抗衰修复护理组合物及其制备方法和应用 | |
CN113274323A (zh) | 一种含植物提取物的化妆品组合物 | |
CN109771326B (zh) | 一种用于美白修护面膜的组合物 | |
CN112294739A (zh) | 一种多效美白组合物及其在润肤霜中的应用 | |
CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
CN113116753A (zh) | 一种玫瑰精油面霜及其制备方法 | |
CN112773740A (zh) | 一种紧致祛皱精华液及其制备方法 | |
CN113069377A (zh) | 一种抗衰老面霜及其制备方法 | |
CN109512765A (zh) | 一种芦荟原汁的保湿油及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211126 |